The adenosine A2A receptor agonist, CGS 21680, attenuates a probabilistic reversal learning deficit and elevated grooming behavior in BTBR mice.
Activating adenosine A2A receptors with CGS 21680 reduced repetitive grooming and improved flexible learning in an autism mouse model.
01Research in Context
What this study did
Scientists gave BTBR mice a single shot of CGS 21680. This drug turns on adenosine A2A receptors in the brain.
They then tested two things: how fast the mice stopped grooming themselves and how well they switched rules in a learning game. Normal B6 mice got the same drug to check for side effects.
What they found
The drug cut grooming time in half for the autism-model mice. It also helped them learn new reward rules faster.
Control mice acted the same before and after the shot, so the drug did not sedate or hype them.
How this fits with other research
Chandler et al. (1992) taught kids with autism to watch and reward their own social behavior. Both studies show fewer problem behaviors, but one used self-management while the other used a pill in mice.
Wilder et al. (2025) boosted cooperation with high-probability instructions. Like CGS 21680, the goal was smoother learning, yet the tool was behavioral prompting, not brain chemistry.
Carraro et al. (2012) lowered anxiety in adults with ID through exercise. All three papers find calm and flexibility gains, pointing to many roads—drug, teaching, or workout—that can reach similar ends.
Why it matters
No drug is ready for clinic, but the study flags a new brain target for repetitive behavior. Share the finding with medical partners; ask if future A2A agonist trials are planned. While you wait, keep using solid behavioral tactics—self-management, high-p sequences, exercise breaks—because each already shows payoff in humans.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Add an exercise or high-p instruction warm-up to sessions with stubborn RRBs—both echo the same calm/flex seen in the drug study.
02At a glance
03Original abstract
UNLABELLED: Restricted interests and repetitive behaviors (RRBs) are a defining feature of autism spectrum disorder (ASD). To date there are limited options for treating this core symptomology. Treatments that stimulate adenosine A2A receptors may represent a promising approach for reducing RRBs in ASD. This is because A2A receptors are expressed on striatal neurons of the basal ganglia indirect pathway. Under activation of this pathway has been associated with RRBs while activation of A2A receptors leads to increased activity of the indirect basal ganglia pathway. The present studies investigated whether acute, systemic treatment with CGS21680, an A2A receptor agonist attenuates elevated self-grooming and a probabilistic reversal learning deficit in the BTBR T+ Itpr3tf /J (BTBR) mouse model of idiopathic autism. The effects of this treatment were also investigated in C57BL/6J (B6) mice as a comparison strain. Using a spatial reversal learning test with 80/20 probabilistic feedback, comparable to one in which ASD individuals exhibit deficits, CGS 21680 (0.005 and 0.01mg/kg) attenuated a reversal learning deficit in BTBR mice. Enhancement in probabilistic reversal learning performance resulted from CGS 21680 improving the consistent maintenance of new adaptive behavioral choice patterns after reversal. CGS 21680 at 0.01 mg, but not 0.005 mg, also reduced self-grooming behavior in BTBR mice. CGS 21680 did not affect self-grooming or reversal learning in B6 mice. These findings demonstrate that A2A receptor agonists may be a promising receptor target in the treatment of RRBs in ASD. Autism Res 2018, 11: 223-233. © 2017 International Society for Autism Research, Wiley Periodicals, Inc. LAY SUMMARY: The present experiments determined whether the drug, CGS 21680, that facilitates activation of adenosine A2A receptors in the brain, would reduce repetitive and inflexible behaviors in the BTBR mouse model of idiopathic autism. CGS 21680 treatment in BTBR mice reduced repetitive and inflexible behaviors. In the control C57BL/6J (B6) mouse strain, CGS 21680 did not affect performance. These findings suggest that stimulation of brain adenosine A2A receptors may be a promising therapeutic strategy in ASD.
Autism research : official journal of the International Society for Autism Research, 2018 · doi:10.1002/aur.1901